179 related articles for article (PubMed ID: 21207416)
1. Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
Liu L; Kron KJ; Pethe VV; Demetrashvili N; Nesbitt ME; Trachtenberg J; Ozcelik H; Fleshner NE; Briollais L; van der Kwast TH; Bapat B
Int J Cancer; 2011 Nov; 129(10):2454-62. PubMed ID: 21207416
[TBL] [Abstract][Full Text] [Related]
2. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
[TBL] [Abstract][Full Text] [Related]
3. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
[TBL] [Abstract][Full Text] [Related]
4. Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids.
Olkhov-Mitsel E; Zdravic D; Kron K; van der Kwast T; Fleshner N; Bapat B
Sci Rep; 2014 Mar; 4():4432. PubMed ID: 24651255
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation of HOXD3 as a marker of prostate cancer progression.
Kron KJ; Liu L; Pethe VV; Demetrashvili N; Nesbitt ME; Trachtenberg J; Ozcelik H; Fleshner NE; Briollais L; van der Kwast TH; Bapat B
Lab Invest; 2010 Jul; 90(7):1060-7. PubMed ID: 20212450
[TBL] [Abstract][Full Text] [Related]
6. Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.
Litovkin K; Joniau S; Lerut E; Laenen A; Gevaert O; Spahn M; Kneitz B; Isebaert S; Haustermans K; Beullens M; Van Eynde A; Bollen M
J Cancer Res Clin Oncol; 2014 Nov; 140(11):1849-61. PubMed ID: 24938434
[TBL] [Abstract][Full Text] [Related]
7. The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies.
Ge YZ; Xu LW; Jia RP; Xu Z; Feng YM; Wu R; Yu P; Zhao Y; Gui ZL; Tan SJ; Song Q
Tumour Biol; 2014 Apr; 35(4):3881-90. PubMed ID: 24353088
[TBL] [Abstract][Full Text] [Related]
8. A quantitative promoter methylation profile of prostate cancer.
Jerónimo C; Henrique R; Hoque MO; Mambo E; Ribeiro FR; Varzim G; Oliveira J; Teixeira MR; Lopes C; Sidransky D
Clin Cancer Res; 2004 Dec; 10(24):8472-8. PubMed ID: 15623627
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.
Bastian PJ; Ellinger J; Wellmann A; Wernert N; Heukamp LC; Müller SC; von Ruecker A
Clin Cancer Res; 2005 Jun; 11(11):4097-106. PubMed ID: 15930345
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.
Balgkouranidou I; Matthaios D; Karayiannakis A; Bolanaki H; Michailidis P; Xenidis N; Amarantidis K; Chelis L; Trypsianis G; Chatzaki E; Lianidou ES; Kakolyris S
Mutat Res; 2015 Aug; 778():46-51. PubMed ID: 26073472
[TBL] [Abstract][Full Text] [Related]
11. Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours.
Juhlin CC; Kiss NB; Villablanca A; Haglund F; Nordenström J; Höög A; Larsson C
PLoS One; 2010 Mar; 5(3):e9472. PubMed ID: 20208994
[TBL] [Abstract][Full Text] [Related]
12. Multigene methylation analysis for detection and staging of prostate cancer.
Enokida H; Shiina H; Urakami S; Igawa M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Sep; 11(18):6582-8. PubMed ID: 16166436
[TBL] [Abstract][Full Text] [Related]
13. Correlation between the expression of DNMT1, and GSTP1 and APC, and the methylation status of GSTP1 and APC in association with their clinical significance in prostate cancer.
Zhang W; Jiao H; Zhang X; Zhao R; Wang F; He W; Zong H; Fan Q; Wang L
Mol Med Rep; 2015 Jul; 12(1):141-6. PubMed ID: 25738352
[TBL] [Abstract][Full Text] [Related]
14. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer.
Kron K; Liu L; Trudel D; Pethe V; Trachtenberg J; Fleshner N; Bapat B; van der Kwast T
Clin Cancer Res; 2012 May; 18(10):2896-904. PubMed ID: 22452941
[TBL] [Abstract][Full Text] [Related]
15. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Minna JD; McConnell J; Frenkel EP; Gazdar AF
Clin Cancer Res; 2002 Feb; 8(2):514-9. PubMed ID: 11839671
[TBL] [Abstract][Full Text] [Related]
16. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
[TBL] [Abstract][Full Text] [Related]
17. High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions.
Martins AT; Monteiro P; Ramalho-Carvalho J; Costa VL; Dinis-Ribeiro M; Leal C; Henrique R; Jerónimo C
Breast Cancer Res Treat; 2011 Aug; 129(1):1-9. PubMed ID: 20842524
[TBL] [Abstract][Full Text] [Related]
18. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients.
Richiardi L; Fiano V; Vizzini L; De Marco L; Delsedime L; Akre O; Tos AG; Merletti F
J Clin Oncol; 2009 Jul; 27(19):3161-8. PubMed ID: 19470943
[TBL] [Abstract][Full Text] [Related]
19. RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer.
Choi N; Son DS; Song I; Lee HS; Lim YS; Song MS; Lim DS; Lee J; Kim H; Kim J
Int J Cancer; 2005 Jul; 115(4):575-81. PubMed ID: 15700308
[TBL] [Abstract][Full Text] [Related]
20. Ras association domain family 1A: a promising prognostic marker in recurrent nonmuscle invasive bladder cancer.
Kim JS; Chae Y; Ha YS; Kim IY; Byun SS; Yun SJ; Kim WJ
Clin Genitourin Cancer; 2012 Jun; 10(2):114-20. PubMed ID: 22382007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
